Yamanaka won the Nobel Prize in 2012. The implications are still being worked out, and they go well past the regenerative-medicine applications that first drew attention. Here’s the part that actually matters: what Yamanaka showed, at bottom, is that aging — at least at the cellular level — may not be chemically fixed. If the epigenetic program running in old cells can be partially reset without triggering cancer, biological age might be far more plastic than anyone assumed. That single possibility is now driving some of the best-funded research programs in medicine, including initiatives backed by Jeff Bezos, Altos Labs ($3 billion and counting), and multiple national health agencies.
Understanding where stem cell biology actually stands — what’s supported, what’s still speculative, and what any of this means practically for someone trying to optimize their biology now, not in fifteen years — means cutting through a fair amount of hype first.
What Stem Cells Are and Why They Matter for Aging
- Hematopoietic stem cells (HSCs) in bone marrow produce all blood cell types — red blood cells, white blood cells, platelets. HSC function is critical for immune maintenance, oxygen-carrying capacity, and wound healing.
- Mesenchymal stem cells (MSCs) give rise to bone, cartilage, fat, and stromal tissue. MSC function maintains skeletal integrity and contributes to tissue repair throughout the body.
- Muscle satellite cells are skeletal muscle’s own stem cells, responsible for repair after injury and for the hypertrophic response to resistance training.
- Neural stem cells (NSCs) maintain neurogenesis in the hippocampus — critical for memory and learning — and potentially other brain regions. NSC function is a target in dementia prevention research.
- Intestinal stem cells rapidly renew the gut epithelium, every 3-5 days, making gut stem cell turnover one of the most metabolically active stem cell processes in the body.
Stem cells have two defining properties: self-renewal (dividing to make more stem cells) and differentiation (producing more specialized cell types). There’s a hierarchy of potency — embryonic stem cells (pluripotent, can become anything), induced pluripotent stem cells (iPSCs, adult cells reprogrammed back to pluripotency), multipotent adult stem cells (several related cell types), and unipotent progenitor cells (one type only).
Adult stem cell populations are the ones that matter most for aging biology. Every tissue keeps a reservoir of them for ongoing maintenance and repair:
Aging brings a progressive decline in all of these adult stem cell populations — what’s termed stem cell exhaustion, one of the nine hallmarks of aging. It shows up as reduced self-renewal (the pool shrinks), impaired differentiation fidelity (stem cells throw off dysfunctional daughter cells), and a weaker response to damage — wounds heal slower, infections clear slower, injured muscle recovers less completely. The functional consequences are just the physical experience of getting older: more infections, slower healing, declining repair capacity, reduced neurogenesis, tissue damage that piles up instead of getting addressed.
Why Stem Cells Decline: The Mechanisms of Stem Cell Aging
Stem cell exhaustion isn’t just cells dying off and not getting replaced. It’s more complicated than that — and, importantly, more reversible than simple attrition would suggest.
Epigenetic drift: Stem cells pick up epigenetic changes with age — shifts in DNA methylation and histone acetylation that alter gene expression without touching the DNA sequence itself. This drift pushes stem cells away from their youthful expression programs toward a more heterogeneous, sloppily regulated state. The striking finding from partial reprogramming research is that reversing this drift, even partially, restores much of the aged stem cell’s function. Which suggests the DNA itself isn’t the damaged part. The program sitting on top of it is what’s aged. And that program, it turns out, can be reset.
Telomere shortening: Stem cells divide to maintain tissue, and every division shortens telomeres — the protective caps on chromosome ends. Once telomeres get critically short, cells enter replicative senescence or apoptosis and drop out of the pool. HSCs in elderly people have measurably shorter telomeres than in young adults, and that shortening limits their replicative capacity. Telomerase — the enzyme that extends telomeres — stays active in many stem cell populations, but its activity declines with age, allowing net shortening over decades.
Mitochondrial dysfunction: Aged stem cells show impaired mitochondrial function — less oxidative phosphorylation capacity, more ROS, accumulating mtDNA mutations. Interestingly, young stem cells prefer anaerobic glycolysis over mitochondrial respiration, which keeps them in a low-ROS, quiescent state. As mitochondrial dysfunction builds with age, that metabolic preference shifts, ROS climbs, and the resulting DNA damage and epigenetic drift further impair function.
Niche deterioration: Stem cells live in specific microenvironments called niches — tissue environments that keep them quiescent, protect them from damage, and signal when to activate. As the surrounding tissue ages, the niche deteriorates: inflammatory signals rise (SASP from senescent cells nearby), blood supply drops, supportive stromal cells stop doing their job well. Aged stem cells transplanted into young niches can regain function — which shows stem cell aging is at least partly a property of the environment, not irreversible damage baked into the cell itself.
Partial Reprogramming: The Most Exciting Development in Aging Biology
The most transformative development in stem cell biology for aging isn’t transplantation or cell therapy. It’s partial cellular reprogramming — using the Yamanaka factors, or other epigenetic reset tools, briefly and not to full pluripotency (which risks cancer), to reverse the epigenetic age of existing cells inside living tissue.
The pivotal experiment came out of David Sinclair’s lab in 2020 (Lu et al., Nature): three of the four Yamanaka factors — OSK, meaning Oct4, Sox2, Klf4, no c-Myc — delivered to retinal ganglion cells in aged mice via a gene therapy vector. The result: damaged, aged retinal neurons regenerated their axons, which normally cannot regenerate in adult mammals, and restored vision in mice with optic nerve crush injury and glaucoma. The cells didn’t turn cancerous or lose their identity. They stayed retinal neurons — just with restored youthful epigenetic patterns and recovered function.
Later work extended the findings. Partial reprogramming in aged mice, delivered systemically or to specific tissues, produced improvements in physical performance, organ function, and multiple aging biomarkers. Juan Carlos Izpisua Belmonte’s group at the Salk Institute showed that periodic expression of the Yamanaka factors in aged mice improved healthspan and extended lifespan without tumor formation. Altos Labs is essentially a $3 billion bet built on exactly this: systematic partial reprogramming protocols meant to restore cellular youth to aged tissues, and to translate that to humans.
If the technology translates, the implications are considerable. Partial reprogramming doesn’t swap aged cells for young ones — it potentially resets the age of the cells that are already there, keeping their identity and function while restoring youthful epigenetic programs. That’s a fundamentally different proposition than cell transplantation. And if it can be done safely in humans, it would be the first genuine biological age reversal technology.
Partial reprogramming is not science fiction — it is published peer-reviewed science that has been independently replicated across multiple labs. The question is not whether it works in animals. The question is whether it can be made safe and practical for humans. That question will likely be answered within the next decade.
Current Stem Cell Therapies: What the Evidence Actually Supports
The gap between the frontier science of partial reprogramming and what’s currently sold in stem cell clinics is enormous. Plenty of clinics offer MSC injections, platelet-rich plasma, umbilical cord blood products — with claims that run well past the evidence. Knowing what’s actually validated by trial data matters here.
Hematopoietic stem cell transplantation (HSCT): The most established, evidence-backed stem cell therapy that exists. Used for decades in hematological cancers, immune deficiency disorders, and increasingly severe autoimmune disease. The mechanisms are well understood, the outcomes data extensive. Not a longevity therapy in the consumer sense — but proof of how powerful stem cell replacement can be when the target tissue is the right one.
Mesenchymal stem cell (MSC) therapies: The most commonly sold stem cell therapy at longevity and regenerative medicine clinics. MSCs get pulled from bone marrow, fat, or umbilical cord tissue, expanded in culture, then infused IV or injected locally. The FDA has approved exactly zero MSC therapies for any condition in the US as of 2024, and the trial evidence for IV MSC infusions marketed for anti-aging or general wellness is essentially nonexistent — the actual published trials are for specific medical conditions (GVHD, COVID-19 lung injury, orthopedic use). The anti-aging MSC clinic industry operates in a regulatory gray zone, limited accountability, no validated outcomes. Billions get spent on this annually against an evidence base that’s still mostly preclinical.
PRP (platelet-rich plasma): Not technically a stem cell therapy, though it gets marketed alongside one. PRP concentrates growth factors from the patient’s own platelets and injects them where there’s tissue damage. Evidence for PRP in orthopedic injuries — tendinopathies, partial muscle tears — is positive but modest; systematic reviews show benefit for specific conditions. The anti-aging application, facial rejuvenation and so on, has weaker support. It’s autologous, so safety concerns are minimal at least.
CAR-T cell therapy: Not a stem cell therapy, strictly speaking, but a form of cellular therapy where T cells get genetically engineered to target cancer cells. FDA-approved for multiple hematological cancers, and remarkably effective in some patient populations. Mostly notable here as proof of how sophisticated cellular engineering has gotten — even operating in a completely different disease context than longevity work.
What You Can Actually Do Now to Support Stem Cell Function
While waiting on reprogramming therapies that might transform aging biology sometime in the next decade — what’s actually available now to maintain adult stem cell populations?
Exercise and muscle satellite cells: Resistance training is the single most potent stimulus for satellite cell activation available to a healthy adult. After the muscle fiber damage resistance training produces, satellite cells activate, proliferate, fuse with damaged fibers, and contribute to repair and hypertrophy. That activation runs on muscle IGF-1, hepatocyte growth factor (HGF), and other local growth factors released during contraction. Training consistently keeps satellite cell responsiveness that would otherwise decline with age — people who’ve trained through their 50s and 60s have far more responsive satellite cell populations than sedentary age-matched peers.
Aerobic exercise and hippocampal neurogenesis: Exercise is the most potent known stimulus for hippocampal neurogenesis in adult mammals. The mechanism runs through BDNF, brain-derived neurotrophic factor, secreted during aerobic exercise, promoting neural stem cell proliferation, survival, and differentiation into new neurons. Declining hippocampal neurogenesis tracks with depression, anxiety, and declining memory, and exercise is one of the more reliable ways to reverse it. Not speculative. One of the most replicated findings in exercise neuroscience.
Sleep and stem cell regeneration: A lot of stem cell renewal is concentrated in sleep. Growth hormone secretion — which drives MSC activation and satellite cell function — peaks during slow-wave sleep. Immune cell turnover, which needs HSC function, runs on circadian rhythms. Glymphatic clearance, the brain’s waste-removal system, depends on adequate sleep and clears the protein aggregates that would otherwise damage neural stem cell niches. Seven to nine hours isn’t optional for stem cell function. It’s the primary window in which stem-cell-dependent tissue maintenance actually happens.
Fasting and stem cell renewal: Prolonged fasting, 24-72 hours, has shown remarkable effects on hematopoietic stem cell function. Valter Longo’s research group found that cycles of fasting (3-4 days) and refeeding drive a dramatic renewal of the immune system in mice — fasting clears out old, dysfunctional immune cells, and refeeding triggers a burst of HSC-dependent regeneration that produces a younger immune repertoire. Human evidence for this specific effect is limited but suggestive. More practically, the fasting-induced autophagy that shows up even with 16-24 hour fasts may help niche quality by clearing out senescent and damaged cells that would otherwise degrade it.
Senolytics and the niche environment: Since senescent cells around stem cell niches are a major driver of niche deterioration, senolytic interventions — dasatinib plus quercetin, fisetin — that reduce senescent cell burden may indirectly protect stem cell function by cleaning up the niche. The rationale is backed by animal experiments where senolytic treatment improved aged stem cell function without touching the stem cells directly.
The Parabiosis Story: Young Blood and Aging Biology
One of the more fascinating lines of evidence for environmental control over stem cell aging comes from parabiosis experiments — surgically joining the circulatory systems of old and young mice so they share blood. These experiments go back decades but were rigorously revisited over the past 15 years, and consistently show young blood reversing multiple features of aging in old mice: satellite cells regain injury responsiveness, liver stem cell function improves, hippocampal neurogenesis increases, and various systemic aging markers improve.
The reverse holds too, and it matters just as much: old blood exposure ages young mice, impairing their stem cell function and accelerating aging phenotypes. Which suggests aged blood isn’t just missing youthful factors — it actively contains factors that suppress stem cell function systemically.
A few specific factors have turned up. GDF11 (growth differentiation factor 11) was initially flagged as a rejuvenating factor present in young blood and declining with age, though later research produced conflicting results on its actual role. Oxytocin was identified by Irina Conboy’s group as a factor that declines with age, and whose supplementation restores muscle and liver stem cell function in old mice. TIMP2 has been identified in umbilical cord plasma as a factor that improves hippocampal function. The emerging picture: young blood is a complex mixture of factors whose combined effect maintains stem cell function, and that mixture shifts systematically with age in ways that progressively suppress the stem cell activity tissue maintenance depends on.
Commercial young plasma therapies have emerged — and been targeted by FDA enforcement actions in the US for unproven claims. The science behind parabiosis is real. The specific protocols sold at commercial clinics are not validated. The more productive direction out of this research is identifying the specific beneficial factors and developing targeted therapies, rather than whole young plasma infusion.
FAQ: Stem Cells and Aging
Honest answer: for most people at most longevity clinics, probably not yet — at least not the unvalidated MSC IV infusions marketed for anti-aging. The evidence base doesn’t support the claims being made, oversight is thin, and safety data in healthy adults at anti-aging doses is scarce. PRP for specific musculoskeletal injuries has more evidence behind it. HSCT for specific hematological or autoimmune conditions is established medicine. Unvalidated whole-body MSC infusions for anti-aging are an entirely different category, with a much weaker evidence base and real risks — immune reactions, infection, injected cells behaving unpredictably.
Q: When will partial reprogramming therapies be available for humans?
Human trials are still early-stage. Validating safety — making sure transient epigenetic reprogramming doesn’t cause tumors, immune reactions, or off-target tissue effects — is a substantial task. Optimistic projections put initial safety trials for specific conditions, potentially age-related vision loss or other localized indications, starting in the late 2020s, with broader applications further out still. The $3 billion Altos Labs investment reflects real confidence in that timeline. But gene therapy’s history — decades of safety hurdles before any approval — counsels some patience.
Q: Does creatine supplementation support muscle stem cell function?
Yes, through an interesting indirect route. Creatine supports satellite-cell-mediated muscle repair by increasing energy availability in muscle fibers during intense exercise and recovery. In older adults, creatine supplementation (3-5 g/day) combined with resistance training produces greater gains in muscle mass and strength than resistance training alone, and that bigger hypertrophic response likely involves enhanced satellite cell activity. Creatine doesn’t directly activate stem cells — it just makes the energy environment more favorable for the satellite-cell-dependent repair process.
Q: Can you increase your stem cell count through lifestyle?
Specific populations can be maintained and partially expanded through the right stimuli. Satellite cells respond to consistent resistance training, and decline with prolonged inactivity. Neural stem cell activity responds to aerobic exercise and cognitive challenge. HSC function responds to good nutrition, sleep, and avoiding chronic inflammation. The goal isn’t maximizing raw stem cell counts — it’s maintaining the functional responsiveness of the populations already there, and the niches that support them. Evidence for genuinely raising stem cell numbers through lifestyle in healthy adults is thin; evidence for maintaining functional responsiveness against age-related decline is substantial.
Q: How do senolytics help stem cell function?
Senescent cells build up in and around stem cell niches and secrete the SASP — senescence-associated secretory phenotype — a mix of inflammatory cytokines and proteases that disrupts the niche, impairs activation, and pushes nearby stem cells toward senescence themselves. Clearing senescent cells with senolytics, dasatinib plus quercetin being the most studied combination, improves the niche and has restored stem cell function in aged mice. In those studies, senolytic treatment restored muscle stem cell responsiveness, improved HSC function, and enhanced physical performance. Human senolytic trials are underway for specific aging-related conditions, and results should clarify how well this translates.
The Epigenetic Clock and Stem Cell Age
One of the more important developments linking stem cell biology to practical aging assessment is the epigenetic clock — DNA methylation-based biomarkers of biological age, developed by Steve Horvath, Morgan Levine, and others. These clocks measure methylation states at hundreds of specific CpG sites across the genome and use the pattern to estimate biological age, which can diverge substantially from chronological age.
The connection to stem cell biology is direct: the epigenetic drift driving stem cell aging is the same process the clocks are measuring. When a clock shows accelerated aging, it’s partly reflecting the epigenetic changes impairing stem cell function and tissue maintenance. When an intervention resets epigenetic age — dramatically, in the case of partial reprogramming in cells, more modestly with some lifestyle interventions in humans — it’s partially reversing the drift underlying stem cell aging.
The practical use of epigenetic clocks for tracking stem cell health is still developing. Current versions — DunedinPACE, GrimAge — measure systemic aging that correlates with stem cell function but don’t isolate tissue-specific populations. As the technology improves, particularly with tissue-specific methylation panels reflecting specific stem cell populations, clocks will become more useful for checking whether an intervention claiming to improve stem cell function is actually doing that.
Right now, the best use of epigenetic clocks is as a systemic aging-rate monitor: tracking DunedinPACE — which measures the pace of biological aging rather than a single point estimate — before and after a lifestyle or pharmacological intervention is the best available proxy for whether that intervention is actually slowing cellular aging across tissue systems. Improvements in DunedinPACE track with improvements in the underlying cellular biology, stem cell biology included.
The Wnt Pathway: A Stem Cell Aging Mechanism You Should Know
With age, Wnt signaling in stem cell niches gets dysregulated — sometimes chronically overactive, which can drive exhaustion by pushing stem cells toward differentiation, sometimes insufficient, which fails to maintain self-renewal. TGF-beta, a cytokine that rises with age and sits elevated in inflammatory environments, suppresses Wnt signaling in muscle satellite cells, impairing their activation after muscle damage. This TGF-beta/Wnt antagonism is one mechanism through which age-related inflammation — inflammaging — directly impairs stem cell function.
Interventions that lower TGF-beta (exercise, which reduces systemic inflammation, among them) or that activate Wnt signaling directly (various pharmaceutical agents in development) represent a way of restoring stem cell function through the niche signaling environment, rather than manipulating the stem cells directly. This niche-targeted approach complements direct stem cell therapies, and may prove more practically translatable in the near term.
Lithium, which at low doses activates Wnt signaling through GSK-3beta inhibition, has drawn attention as a potential stem-cell-function-supporting intervention. Low-dose lithium — far beneath the psychiatric therapeutic range, a tiny fraction of what gets prescribed for mood disorders — has shown interesting effects on brain aging in epidemiological studies (populations drinking lithium-rich water show lower rates of neurodegenerative disease) and in some animal aging models. Whether this reflects Wnt-mediated neural stem cell support is speculative. But the signal is interesting enough that it’s being actively researched.
Nutrition and Stem Cell Health
Diet affects stem cell function through several mechanisms, and the nutritional inputs deserve explicit attention.
Caloric restriction extends the functional lifespan of multiple stem cell populations in animal models. The mechanisms: reduced mTOR activation, which when chronically elevated pushes stem cells toward differentiation and away from self-renewal; reduced oxidative stress and DNA damage accumulation; and maintenance of the quiescent state, where stem cells are best protected from metabolic damage. Translating strict caloric restriction to humans is hard. But the mechanistic case for avoiding chronic caloric excess — which drives many of the same adverse effects as CR’s absence would — is strong.
Protein intake and amino acid sensing regulate stem cell function through mTOR-dependent mechanisms. High leucine intake chronically activates mTOR in stem cell populations, pushing them toward differentiation and exhausting the self-renewing pool. Periodic protein restriction, as in fasting-mimicking diets, lets mTOR fall and allows stem cells to reset toward a more self-renewing state. This is the mechanistic basis for Longo’s fasting-mimicking diet effects on HSC renewal — the 4-day near-fast creates a window of mTOR suppression during which damaged immune cells clear out and the HSC pool partially replenishes.
Polyphenols and stem cell niche protection: Several dietary polyphenols have evidence for protecting niche environments by cutting inflammation and oxidative stress. Quercetin (apples, onions, capers), fisetin (strawberries, apples, persimmons), apigenin (parsley, chamomile), and resveratrol (grapes, red wine) all carry animal evidence for reducing senescent cell burden in niches and maintaining niche quality. The evidence is strongest for quercetin and fisetin as senolytic agents — clearing the senescent cells degrading niches — rather than as direct stem cell activators.
Omega-3 fatty acids (EPA and DHA) have specific evidence supporting hematopoietic stem cell function and reducing the inflammatory environment that impairs niches systemically. In aged mice, omega-3 supplementation improved HSC function and reduced age-related clonal hematopoiesis — the expansion of HSC clones carrying mutations that confer a growth advantage, an age-related phenomenon linked to cardiovascular disease and cancer risk. Whether the human equivalent of these doses, roughly 3-4 grams of combined EPA/DHA daily, produces similar effects is still being studied.
The Bigger Picture: Aging as a Stem Cell Problem
The emerging view in biogerontology is that a lot of the most consequential physical hallmarks of aging — declining immune function, muscle loss, reduced neuroplasticity, impaired wound healing, rising cancer risk — trace back, at least in part, to the progressive exhaustion of adult stem cell populations and the deterioration of the niches that support them.
This framing cuts both ways. Sobering, because stem cell exhaustion is one of the slower, deeper aging processes — not easily reversed by lifestyle choices alone, not with current tools anyway. Empowering, because many of the interventions with the strongest evidence for aging benefit — exercise, fasting, sleep, inflammation reduction, senolytics — work substantially through their effects on stem cell function and niche preservation. Committing to consistent resistance training, keeping metabolic health in order, prioritizing sleep, cutting chronic inflammation — that already is stem cell medicine.
The future will bring more targeted tools: partial reprogramming, niche-specific growth factors, senolytic-senomorphic combinations, gene therapies for specific populations. The next decade should see the first human trials of these approaches, and early evidence of safety and efficacy. In the meantime, the lifestyle interventions that protect stem cell function and niche integrity aren’t a holding pattern while better technology arrives. They’re the current standard of care for stem cell biology — and they matter more than most people give them credit for.
Yamanaka’s 2006 discovery showed that cells can be younger than their years. The field built on it is showing how. Making the cells inside a living, aging human body younger — without making them cancerous or undifferentiated — is the central challenge facing the next generation of medicine. Early days still. But early doesn’t mean irrelevant. The science is real, the direction is clear, and the tools already available are meaningful for anyone willing to use them.
Clonal Hematopoiesis: The Age-Related Stem Cell Risk You Should Know
One of the more practically important recent discoveries in stem cell aging is clonal hematopoiesis of indeterminate potential, CHIP — the age-related expansion of blood cell clones derived from hematopoietic stem cells carrying acquired somatic mutations. CHIP affects roughly 10% of people over 65 and nearly 20% of people over 70. It’s detectable via next-generation sequencing of blood cells, and it’s associated with a 10-fold increased risk of hematological cancer and, more surprisingly, a 2-4x increased risk of cardiovascular disease and all-cause mortality.
The cardiovascular risk from CHIP runs through a different mechanism than the cancer risk. CHIP-associated mutations — most commonly in DNMT3A, TET2, ASXL1, and JAX2 — drive production of inflammatory macrophages that infiltrate atherosclerotic plaques, accelerating plaque instability and cardiovascular events. Inflammatory macrophages from mutant HSC clones produce more IL-6, IL-1beta, and other inflammatory cytokines than normal macrophages — accelerating both vascular disease and systemic inflammaging.
CHIP isn’t currently treatable. No intervention has been shown to reduce clonal burden or change the natural history of established CHIP. But it’s one of the clearest examples of stem cell aging producing systemic disease risk well beyond the tissue where the stem cells actually reside. What appears to reduce CHIP risk: regular aerobic exercise, which reduces HSC mutation accumulation and may reduce the selective advantage of mutant clones, and avoiding genotoxic exposures — smoking, chronic alcohol, radiation. An area where targeted interventions will likely emerge as the field matures.
For people over 60 with cardiovascular risk factors or cancer in the family, CHIP screening via a simple blood test — $200-500 through specialty labs — can offer useful risk stratification. Knowing your CHIP status doesn’t change the intervention landscape much today, but it’s a highly personalized risk signal that’ll become more actionable as CHIP-targeted therapies develop. The kind of thing that, in five or ten years, will look like an obvious thing to have measured decades earlier — the way early statin and blood pressure treatment look obviously valuable in hindsight now.
The stem cell story is, ultimately, a story about the biological basis of the body’s capacity for renewal — and how that capacity can be protected, supported, and eventually restored. The tools are coming. The biology is being worked out. And the choices made today about exercise, sleep, diet, and inflammation are writing the first chapters of how those stem cell populations will function decades from now.
The researchers working on partial reprogramming aren’t naive optimists chasing immortality fantasies. They’re rigorous scientists who’ve replicated extraordinary findings across multiple model systems and are now translating them carefully into human biology. The pace of progress in this field over the past five years has been genuinely unprecedented. If it continues, the next decade should see the first clinical demonstrations that biological age reversal is achievable in humans — not as a metaphor, but as a measurable biological fact. Understanding the stem cell biology underneath it makes the evidence clearer, and the stakes a good deal more concrete.
The Practical Framework: Applying Stem Cells Actually In Real Life
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map